A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Obeticholic acid (OCA), a potent farnesoid X receptor agonist, was studied as monotherapy in an international, randomized, double‐blind, placebo‐controlled phase 2 study in patients with primary biliary cholangitis who were then followed for up to 6 years. The goals of the study were to assess the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowdley, Kris V., Luketic, Velimir, Chapman, Roger, Hirschfield, Gideon M., Poupon, Raoul, Schramm, Christoph, Vincent, Catherine, Rust, Christian, Parés, Albert, Mason, Andrew, Marschall, Hanns‐Ulrich, Shapiro, David, Adorini, Luciano, Sciacca, Cathi, Beecher‐Jones, Tessa, Böhm, Olaf, Pencek, Richard, Jones, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947631/
https://www.ncbi.nlm.nih.gov/pubmed/29023915
http://dx.doi.org/10.1002/hep.29569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947631/
https://www.ncbi.nlm.nih.gov/pubmed/29023915
http://dx.doi.org/10.1002/hep.29569

Ejemplares similares